Disparity in the Markers of Affordability Across Targeted‐ and Immune‐Therapy Drugs Used in Head and Neck Cancers
Head & Neck · 2026-07 · 48 (7) · 1876-1884
DOI: 10.1002/hed.70212 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Head & Neck, online erschienen am 26.02.2026. Verfasst von Arjun Gurmeet Singh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Oncology, Tata Memorial Centre and HBNI, Mumbai, India. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Immunotherapy, Health Services Accessibility, Healthcare Disparities. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The expanding use of systemic therapies for recurrent and metastatic head and neck cancer has raised major concerns regarding affordability and equitable access, particularly across countries with differing income levels and health financing structures.
Methods
We conducted a comparative affordability and budget‐reach analysis of commonly used systemic agents—pembrolizumab, nivolumab, cetuximab, gefitinib, and erlotinib—across seven countries (United States, United Kingdom, Australia, South Africa, India, Pakistan, and Bangladesh) representing high‐, upper‐middle‐, and lower‐middle‐income settings.
Results
Immunotherapy was unaffordable across all settings. Six‐month pembrolizumab costs corresponded to 7994% of monthly income in India, 4311% in Pakistan, 3133% in Bangladesh, and remained above catastrophic thresholds in high‐income countries (591% in the United States; 903% in the United Kingdom). In contrast, oral tyrosine kinase inhibitors were substantially less costly, with gefitinib requiring 171%–412% of monthly income in South Asia and falling below thresholds in Pakistan and Bangladesh. The cost of treating one patient with pembrolizumab could fund treatment for 18–22 patients with gefitinib in South Asia.
Conclusions
Despite modest survival benefits, current immunotherapy pricing severely limits global accessibility. Policy reform and pricing strategies are needed to ensure equitable cancer care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Head and Neck Oncology, Tata Memorial Centre and HBNI, Mumbai, India.
- Cancer Policy & Global Health, Kings Institute of Cancer Policy, London, UK.
- Department of Radiation Oncology, Tata Memorial Centre and HBNI, Mumbai, India.
- Department of Medical Oncology, Tata Memorial Centre and HBNI, Mumbai, India.
ORCID-Profile: Arjun Gurmeet Singh, Poonam Joshi, Sudhir Nair, Sarbani Ghosh Laskar, Pankaj Chaturvedi
Zitieren
APA
Singh, A. G., Kole, L., Sullivan, R., Sinha, S., Shetty, R., Joshi, P., Nair, S., Laskar, S. G., Prabhash, K., & Chaturvedi, P. (2026). Disparity in the Markers of Affordability Across Targeted‐ and Immune‐Therapy Drugs Used in Head and Neck Cancers. Head & Neck, 48(7), 1876-1884. https://doi.org/10.1002/hed.70212
Vancouver
Singh AG, Kole L, Sullivan R, Sinha S, Shetty R, Joshi P, et al. Disparity in the Markers of Affordability Across Targeted‐ and Immune‐Therapy Drugs Used in Head and Neck Cancers. Head & Neck. 2026;48(7):1876-1884. doi:10.1002/hed.70212
BibTeX
@article{Singh2026,
author = {Singh, Arjun Gurmeet and Kole, Labani and Sullivan, Richard and Sinha, Shwetabh and Shetty, Rathan and Joshi, Poonam and Nair, Sudhir and Laskar, Sarbani Ghosh and Prabhash, Kumar and Chaturvedi, Pankaj},
title = {Disparity in the Markers of Affordability Across Targeted‐ and Immune‐Therapy Drugs Used in Head and Neck Cancers},
journal = {Head & Neck},
year = {2026},
volume = {48},
number = {7},
pages = {1876--1884},
doi = {10.1002/hed.70212}
}
EUVIMED